Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: Retrospective analysis

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 287-293

  Sakamoto, Takeshi ^a   Yasui, Hirofumi ^a   Boku, Narikazu ^a   Onozawa, Yusuke ^a   Hironaka, Shuichi ^a   Fukutomi, Akira ^a   Yamazaki, Kentaro ^a   Taku, Keisei ^a   Machida, Nozomu ^a   Todaka, Akiko ^a   Tomita, Hideharu ^a   Tsushima, Takahiro ^a   Taniguchi, Hiroya ^a   Hamauchi, Satoshi ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Cisplatin; Gastric cancer; Irinotecan; Pretreated

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INOPERABLE CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RADIOGRAPHY; STOMACH NEOPLASMS; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; KAPLAN-MEIER ESTIMATE;

EID: 77955716368     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0054-9     Document Type: Article

References (16)

1. Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168
2. Pyrhonen S, Kuitunen T, Nyandoto P et al (1995) Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
3. Murad AM, Santiago FF, Petroianu A et al (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41
4. Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063-1069
5. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221
6. Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820
7. Hsiang YH, Liu LF, Wall ME et al (1989) DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49:4385-4389
8. Thuss-Patience PC, Kretzschmar A, Deist T et al (2009) Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol 27:15(Suppl) abstr 4540
9. Boku N, Ohtsu A, Shimada Y et al (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319
10. Ueda S, Hironaka S, Boku N et al (2006) Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer. Gastric Cancer 9:203-207
11. Koizumi W, Kurihara M, Satoh A et al (2005) Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer. Anticancer Res 25:1257-1262
12. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216 (Pubitemid 30099779)
13. Futatsuki K, Wakui A, Nakao I et al (1994) Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 21:1033-1038
14. Yoshida T, Yoshikawa T, Tsuburaya A et al (2006) Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxelrefractory, metastatic gastric cancer. Anticancer Res 26:1595-1598
15. Nakae S, Hirao M, Kishimoto T et al (2008) Phase II study of biweekly CPT-11?CDDP for patients with gastric cancer refractory to S-1 (OGSG 0504 study). J Clin Oncol 26:(May 20 Suppl) abstr 4571
16. Arai T, Hamaguchi T, Shirao K et al (2003) Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc Am Soc Clin Oncol 22:321